Whitepapers

Articles

In this study, HEK293F cells grown in scale-X bioreactor produce >3x higher AAV-2 vector, with 25-52% lower cost than the reference process. 

AAV Manufacturing: The benefits of growing serum-free, suspension HEK293 cells in the scale-X™ fixed-bed bioreactor

This study aims to evaluate harvest strategies and metabolite-based cell density estimation methods for Lentivirus production with HEK293T cells.

Lentivirus production study in the scale-X™ fixed-bed bioreactor 

BridgeBio Pharma, Inc., and REGENXBIO Inc. take a novel approach to AAV capsid titer quantification by using Octet® AAVX Biosensors to generate viral titer data. 

Rapid and Direct Quantitation of AAV Capsids Using Octet® BLI

Discover how the Ramina Process Analyzer integrates with the 500L HyPerforma DynaDrive bioreactor to perform accurate in-line measurements and prediction models.

Metabolite Monitoring with Ramina Process Analyzer

This application note examines the suitability of BioBLU® 0.3c Single-Use Bioreactors and the DASbox Mini Bioreactor System in the long-term expansion of CD4+ T cells. 

T Cell expansion in the DASbox® Mini Bioreactor System

This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.

Scalable rubella production in scale-X™ bioreactor with MRC-5 cells (Nov 2022)

Scalable rubella production in scale-X™ bioreactor with MRC-5 cells

The combination of the PentaMice® platform and single B cell screening with the Beacon® system increases speed to market for monoclonal antibody antibody therapeutics. 

Antibody-based drug discovery at the speed of light

This application note explores the feasibility of utilizing the scale-X carbo bioreactor as a solution for seed train intensification.

Scalable seed train intensification and automation for adherent cell cultures

Using the BioAccord LC-MS System and an Ambr® 15, we developed an analytical method for rapid mAb glycoform confirmations and mAb purity assessments. This unique method is high throughput capable and has the potential to be a fully automated platform for mid-process intraday monitoring of CQAs.


Upstream Processing Whitepapers